Medtronic announces intent to separate diabetes business

Enables intense focus on highest margin growth drivers where medtronic has leading core competencies leading, scaled, direct-to-consumer diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management galway, ireland , may 21, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced its intent to separate its diabetes business into a new standalone company ("new diabetes company"). this strategic decision for both medtronic and new diabetes company will create a more focused medtronic, with a more simplified portfolio in high margin growth markets.
MDT Ratings Summary
MDT Quant Ranking